[go: up one dir, main page]

MX378354B - IMPROVEMENT OF AUTOPHAGY OR INCREASE IN LONGEVITY BY ADMINISTRATION OF UROLITINS OR PRECURSORS THEREOF. - Google Patents

IMPROVEMENT OF AUTOPHAGY OR INCREASE IN LONGEVITY BY ADMINISTRATION OF UROLITINS OR PRECURSORS THEREOF.

Info

Publication number
MX378354B
MX378354B MX2014016044A MX2014016044A MX378354B MX 378354 B MX378354 B MX 378354B MX 2014016044 A MX2014016044 A MX 2014016044A MX 2014016044 A MX2014016044 A MX 2014016044A MX 378354 B MX378354 B MX 378354B
Authority
MX
Mexico
Prior art keywords
urolithin
precursors
autophagy
longevity
urolitins
Prior art date
Application number
MX2014016044A
Other languages
Spanish (es)
Other versions
MX2014016044A (en
Inventor
Bernard Schneider
Rinsch Christopher L
Dongryeol Ryu
Johan Auwerx
Laurent Mouchiroud
Penelope Andreux
William Blanco-Bose
Original Assignee
Amazentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48782652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX378354(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amazentis Sa filed Critical Amazentis Sa
Publication of MX2014016044A publication Critical patent/MX2014016044A/en
Publication of MX378354B publication Critical patent/MX378354B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)

Abstract

Disclosed are methods, compounds, and compositions useful for increasing autophagy and promoting longevity. The methods, compounds, and compositions relate to urolithins and urolithin precursors and use thereof. Certain urolithins are represented by Formula I, while certain urolithin precursors are represented by Formula IV. The urolithin may be urolithin A, urolithin B, urolithin C, or urolithin D. The urolithin precursor may be ellagic acid or an ellagitannin. The methods include in vivo, ex vivo, and in vitro uses of the compounds and compositions.
MX2014016044A 2012-06-27 2013-06-27 IMPROVEMENT OF AUTOPHAGY OR INCREASE IN LONGEVITY BY ADMINISTRATION OF UROLITINS OR PRECURSORS THEREOF. MX378354B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261665137P 2012-06-27 2012-06-27
US201261712886P 2012-10-12 2012-10-12
US201361791137P 2013-03-15 2013-03-15
PCT/US2013/048310 WO2014004902A2 (en) 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof

Publications (2)

Publication Number Publication Date
MX2014016044A MX2014016044A (en) 2015-05-12
MX378354B true MX378354B (en) 2025-03-10

Family

ID=48782652

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2014016044A MX378354B (en) 2012-06-27 2013-06-27 IMPROVEMENT OF AUTOPHAGY OR INCREASE IN LONGEVITY BY ADMINISTRATION OF UROLITINS OR PRECURSORS THEREOF.
MX2020008468A MX393128B (en) 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
MX2022007264A MX2022007264A (en) 2012-06-27 2014-12-19 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2020008468A MX393128B (en) 2012-06-27 2013-06-27 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
MX2022007264A MX2022007264A (en) 2012-06-27 2014-12-19 Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof.

Country Status (16)

Country Link
US (9) US11020373B2 (en)
EP (3) EP4566677A2 (en)
JP (4) JP6422163B2 (en)
KR (4) KR102163091B1 (en)
CN (2) CN105142632B (en)
AR (1) AR091604A1 (en)
AU (6) AU2013284419A1 (en)
BR (1) BR112014032809A8 (en)
CA (2) CA2877718C (en)
DK (1) DK4233858T3 (en)
ES (2) ES2968368T3 (en)
MX (3) MX378354B (en)
PL (1) PL4233858T3 (en)
PT (2) PT2866804T (en)
SG (3) SG11201408539UA (en)
WO (1) WO2014004902A2 (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2866804T (en) * 2012-06-27 2023-12-18 Amazentis Sa IMPROVEMENT OF AUTOPHAGY OR INCREASE OF LONGEVITY BY ADMINISTRATION OF UROLITHINS OR THEIR PRECURSORS
AU2014206777A1 (en) * 2013-01-18 2015-07-09 Procell Sprl Urolithin B for muscle growth
HK1222590A1 (en) * 2013-09-09 2017-07-07 Natreon, Inc. Regulation of body weight gain by using dibenzo-alpha-pyrones
EP2862568A1 (en) * 2013-10-15 2015-04-22 Centre National de la Recherche Scientifique (CNRS) Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion
CA2972013C (en) 2013-12-23 2020-04-28 Amazentis Sa Process-scale synthesis of urolithins
GB201323008D0 (en) 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201413228D0 (en) 2014-07-25 2014-09-10 Nugerontix Ltd Polyphenol compositions
CN107427488A (en) * 2014-12-19 2017-12-01 光环生命科学有限公司 Purposes of the ellagic acid dihydrate in food and health products
US10364206B2 (en) 2015-04-13 2019-07-30 Sumitomo Seika Chemicals Co., Ltd. Method for producing 2-halogenated benzoic acids
JP6740548B2 (en) * 2015-05-15 2020-08-19 公立大学法人岡山県立大学 Hair growth agent containing urolithins, and 5α reductase activity inhibitor containing urolithins
JP2017014154A (en) * 2015-07-01 2017-01-19 公立大学法人岡山県立大学 Hyaluronic acid production promoter containing urolithins
JP6799767B2 (en) * 2015-07-07 2020-12-16 公立大学法人岡山県立大学 Melanin production inhibitor containing urolithins
GB201515391D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
US11166972B2 (en) * 2015-12-24 2021-11-09 Amazentis Sa Compositions comprising nicotinamide riboside and a urolithin
JP6791478B2 (en) * 2016-05-26 2020-11-25 株式会社ダイセル Angiotensin converting enzyme inhibitor containing urolithins
JP2017210444A (en) * 2016-05-26 2017-11-30 株式会社ダイセル Lipase inhibitor containing urolithin
EP3478091B1 (en) * 2016-06-29 2024-03-20 Halo Life Science, LLC Method of preparing a low odor dicholinium ellagate salt and other low odor organic salts of choline
US10774328B2 (en) 2016-07-11 2020-09-15 University Of North Texas Health Science Center At Fort Worth Treatment for glaucoma and other eye diseases
US11634686B2 (en) 2016-11-01 2023-04-25 Jian Feng Method of producing naive pluripotent stem cells
EP3354645A1 (en) 2017-01-26 2018-08-01 Patheon Austria GmbH & Co KG Process for preparing urolithins
EP3592425A1 (en) * 2017-03-08 2020-01-15 Amazentis SA Methods for improving mitophagy in subjects
CN110709077A (en) 2017-03-08 2020-01-17 阿马曾提斯公司 skin treatments
EP3592424A1 (en) * 2017-03-08 2020-01-15 Amazentis SA Methods for improving mitophagy in subjects
JP2019097566A (en) * 2017-12-07 2019-06-24 大正製薬株式会社 Composition for regulating biological clock
WO2019121855A1 (en) * 2017-12-20 2019-06-27 Societe Des Produits Nestle S.A. Compositions and methods using high protein for induction of autophagy
BR112020009765A2 (en) * 2017-12-20 2020-11-03 Société des Produits Nestlé S.A. compositions and methods that use a combination of autophagy inducer and high protein content for inducing autophagy
JP2022500347A (en) * 2018-02-19 2022-01-04 ナトレオン，インコーポレイテッド Synergistic combination of urolithin A and B to improve cognitive or cognitive function
WO2019163437A1 (en) 2018-02-21 2019-08-29 株式会社ダイセル Osteoclast differentiation inhibitor containing urolithin
CN112074510A (en) * 2018-02-27 2020-12-11 阿马曾提斯公司 Industrial-Scale Synthesis of urolithin A
WO2019187918A1 (en) * 2018-03-29 2019-10-03 国立大学法人 琉球大学 Method for preventing incorporation of undifferentiated ips cells possibly having tumorigenic potential using differentiation-controlling compound
BR112020022159A2 (en) * 2018-04-30 2021-01-26 Amazentis Sa urolithin a as an immune enhancer
CA3100335A1 (en) * 2018-05-15 2019-11-21 University Of Louisville Research Foundation, Inc. Urolithin a and derivatives thereof for use in therapy
JP7377220B2 (en) 2018-06-05 2023-11-09 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド Active agents and methods of their use for the treatment of metabolic disorders and non-alcoholic fatty liver disease
JP2021527048A (en) * 2018-06-05 2021-10-11 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド Acylated catechin polyphenols for cancer treatment and how to use them
CN108676013B (en) * 2018-06-25 2021-01-01 中国医学科学院医药生物技术研究所 Flavonoids with autophagy-activating activity, preparation method and pharmaceutical application thereof
CN109316478A (en) * 2018-11-06 2019-02-12 上海出入境检验检疫局动植物与食品检验检疫技术中心 The application and drug, cosmetics of a kind of urolithin A in the drug, cosmetics of preparation anti-aging
PL245399B1 (en) 2018-11-29 2024-07-15 Univ Warszawski Medyczny Pharmaceutical composition containing urolithin A or its derivative for external topical use in the treatment, inhibition and prevention of inflammatory diseases of the skin and mucous membranes
WO2020148445A1 (en) * 2019-01-18 2020-07-23 Société des Produits Nestlé S.A. Agents and methods for increasing stem cell function
CN110066284B (en) * 2019-02-01 2021-06-04 贵阳倍隆生物科技有限公司 Method for synthesizing ellagic acid by one-pot method
CN110229167B (en) * 2019-05-22 2020-11-24 珠海萱嘉君行健康产业发展有限公司 A kind of method for preparing ellagic acid by utilizing gallnut, obtained ellagic acid and application thereof
CN111995610A (en) * 2019-05-27 2020-11-27 首都医科大学 Application of urolithin compound in medicine for treating glioblastoma
EP3986420A1 (en) * 2019-06-18 2022-04-27 Mitopower LLC Nicotinyl riboside compounds and their uses
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
GB201912107D0 (en) * 2019-08-22 2019-10-09 Amazentis Sa Combination
GB201915191D0 (en) * 2019-10-21 2019-12-04 Floratek Gmbh Novel heterocyclic compounds
GB201916046D0 (en) 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
EP4065103A1 (en) * 2019-11-27 2022-10-05 Société des Produits Nestlé S.A. Direct ampk activator compounds combined with indirect ampk activator compounds, compositions, methods and uses thereof
CN114727980A (en) * 2019-11-27 2022-07-08 雀巢产品有限公司 Benzocoumarin AMPK activator compounds, compositions, methods and uses thereof
CN113018305A (en) * 2019-12-24 2021-06-25 兰州大学 Application of compound in preparation of medicine for treating Alzheimer's disease
WO2021163802A1 (en) * 2020-02-20 2021-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Use of castalagin or analogs thereof for anti-cancer efficacy and to increase the response to immune checkpoint inhibitors
US20240000753A1 (en) * 2020-07-17 2024-01-04 The Trustees Of Columbia University In The City Of New York Methods and compositions to increase lifespan and healthspan by mimicking the effects of time-restricted feeding
CN111983058B (en) * 2020-07-30 2023-06-23 云南中医药大学 Screening method for anti-nonalcoholic fatty liver active substances of traditional Chinese medicine
US20220071952A1 (en) * 2020-09-04 2022-03-10 Natreon, Inc. Methods of treating and preventing hepatotoxicity
CA3188397A1 (en) 2020-09-25 2022-03-31 Anupama Dattatreya Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
KR102623664B1 (en) 2020-12-10 2024-01-12 서울대학교산학협력단 Composition and treatment method for diabetic Alzheimer's disease using urolitin A
CN117015530A (en) 2021-01-27 2023-11-07 范徳利亚股份公司 Urolithin derivatives and methods of use thereof
CN112716938A (en) * 2021-02-25 2021-04-30 新疆医科大学 Application of ellagic acid in preparing medicine for relieving ocular tissue pathological changes
KR102677423B1 (en) * 2021-09-17 2024-06-21 조선대학교산학협력단 Composition for activating autophagy comprising mangiferin
KR102690860B1 (en) * 2021-10-13 2024-08-05 한국해양과학기술원 Composition for Preventing or Treating Inflammatory Diseases Comprising Metabolites from Antarctic Fungal Strain Pleosporales sp. SF-7343
AU2022378931A1 (en) * 2021-10-28 2024-02-22 Société des Produits Nestlé S.A. Compositions and methods using a combination of nutrients to support cognition and emotional health in a mammal
EP4482947A1 (en) 2022-02-24 2025-01-01 Amazentis SA Uses of urolithins
EP4496562A1 (en) 2022-03-22 2025-01-29 Amazentis SA Compositions
JP2025521186A (en) * 2022-06-06 2025-07-08 アマゼンティス エスアー Urolithins for Improving Cardiac Function and Health
IL318574A (en) * 2022-07-27 2025-03-01 Vandria Sa Therapeutic uses of urolithin derivatives
CN115433151A (en) * 2022-09-02 2022-12-06 苏州大学 A kind of preparation method of 6,7,8-trihydroxycoumarin
CN115581689B (en) * 2022-10-17 2024-05-14 常州大学 Application of urolithin B amide derivatives
GB202219317D0 (en) 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
GB202312220D0 (en) 2023-08-09 2023-09-20 Amazentis Sa Formulation
WO2025076497A1 (en) * 2023-10-06 2025-04-10 Northeast Ohio Medical University Combination treatment of tau pathology
WO2025078645A1 (en) * 2023-10-13 2025-04-17 L'oreal Cosmetic use of at least urolithin b or c on a sensitive skin
FR3153998A1 (en) * 2023-10-13 2025-04-18 L'oreal Cosmetic use of iso-urolithin A on sensitive skin
FR3153997A1 (en) * 2023-10-13 2025-04-18 L'oreal Cosmetic use of at least urolithin B on sensitive skin
FR3153996A1 (en) * 2023-10-13 2025-04-18 L'oreal Cosmetic use of at least urolithin C on sensitive skin
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use
CN117771237B (en) * 2024-02-27 2024-05-03 南昌医学院 Application and preparation method of abietane diterpenoid compound

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6479103A (en) 1987-06-09 1989-03-24 Lion Corp External preparation
CA2338638C (en) 1998-07-30 2009-03-17 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
US6440436B1 (en) 2001-05-18 2002-08-27 Natreon Inc. Process for preparing purified shilajit composition from native shilajit
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
US8475776B2 (en) 2005-04-28 2013-07-02 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
WO2007127263A2 (en) * 2006-04-26 2007-11-08 The Regents Of The University Of California Therapeutic uses of urolithins
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
WO2008139123A2 (en) * 2007-05-11 2008-11-20 Galderma Research & Development Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
TW200929211A (en) 2007-12-17 2009-07-01 Etron Technology Inc Method of reducing current of memory in self-refreshing mode
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
CA2719853A1 (en) 2008-03-25 2009-10-01 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
JP5385686B2 (en) 2009-06-05 2014-01-08 サントリーホールディングス株式会社 Platelet aggregation inhibitor
NZ598290A (en) * 2009-07-24 2014-12-24 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
CN113142581B (en) * 2010-12-23 2025-07-22 阿马曾提斯公司 Compositions and methods for improving mitochondrial function
WO2012113835A1 (en) 2011-02-22 2012-08-30 Institut National De La Sante Et De La Recherche Medicale (Inserm) C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection
PT2866804T (en) 2012-06-27 2023-12-18 Amazentis Sa IMPROVEMENT OF AUTOPHAGY OR INCREASE OF LONGEVITY BY ADMINISTRATION OF UROLITHINS OR THEIR PRECURSORS
US11166972B2 (en) 2015-12-24 2021-11-09 Amazentis Sa Compositions comprising nicotinamide riboside and a urolithin

Also Published As

Publication number Publication date
MX2014016044A (en) 2015-05-12
US20230233523A1 (en) 2023-07-27
AU2020200420B2 (en) 2021-11-11
US20230390238A1 (en) 2023-12-07
US20250228817A1 (en) 2025-07-17
KR20150036224A (en) 2015-04-07
KR20230116091A (en) 2023-08-03
ES3032009T3 (en) 2025-07-14
US9962366B2 (en) 2018-05-08
MX2022007264A (en) 2022-07-13
SG11201408539UA (en) 2015-01-29
WO2014004902A3 (en) 2014-03-06
AU2018202407A1 (en) 2018-04-26
JP6879980B2 (en) 2021-06-02
SG10202106329TA (en) 2021-07-29
US20210353591A1 (en) 2021-11-18
AU2022200876B2 (en) 2024-08-15
JP2023107934A (en) 2023-08-03
US20180015069A1 (en) 2018-01-18
AU2018200791A1 (en) 2018-02-22
SG10201610798QA (en) 2017-02-27
WO2014004902A2 (en) 2014-01-03
JP7339296B2 (en) 2023-09-05
AU2022200876A1 (en) 2022-03-03
US11931336B2 (en) 2024-03-19
US20160000753A1 (en) 2016-01-07
JP2015523362A (en) 2015-08-13
CN105142632B (en) 2020-01-07
PT2866804T (en) 2023-12-18
CA2877718A1 (en) 2014-01-03
BR112014032809A8 (en) 2021-06-22
EP2866804A2 (en) 2015-05-06
JP6422163B2 (en) 2018-11-14
MX2020008468A (en) 2022-06-14
ES2968368T3 (en) 2024-05-09
AR091604A1 (en) 2015-02-18
CA2877718C (en) 2021-10-12
EP4233858A1 (en) 2023-08-30
US20200397748A1 (en) 2020-12-24
US20250228816A1 (en) 2025-07-17
PL4233858T3 (en) 2025-06-09
DK4233858T3 (en) 2025-05-12
EP2866804B1 (en) 2023-09-13
CN105142632A (en) 2015-12-09
EP4566677A2 (en) 2025-06-11
AU2013284419A1 (en) 2015-02-12
AU2024259763A1 (en) 2024-11-21
AU2020200420A1 (en) 2020-03-05
KR102163091B1 (en) 2020-10-08
JP2018184455A (en) 2018-11-22
US11020373B2 (en) 2021-06-01
US11931335B2 (en) 2024-03-19
MX393128B (en) 2025-03-24
KR20210128511A (en) 2021-10-26
CN110934863A (en) 2020-03-31
BR112014032809A2 (en) 2017-06-27
PT4233858T (en) 2025-05-15
US20140018415A1 (en) 2014-01-16
JP2021119180A (en) 2021-08-12
CA3127211A1 (en) 2014-01-03
AU2018200791B2 (en) 2019-10-31
AU2018202407B2 (en) 2019-11-21
KR102317160B1 (en) 2021-10-25
EP4233858B1 (en) 2025-02-12
KR20200116176A (en) 2020-10-08

Similar Documents

Publication Publication Date Title
MX378354B (en) IMPROVEMENT OF AUTOPHAGY OR INCREASE IN LONGEVITY BY ADMINISTRATION OF UROLITINS OR PRECURSORS THEREOF.
UY33776A (en) 1-BENCILCICLOALQUILCARBOXÍLICOS ACIDS SUBSTITUTED AND ITS USE
CR20140238A (en) NUCLEOSID DERIVATIVES WITH REPLACEMENT 2´, 4´- DIFLUORO-2´-METHYL AS INHIBITORS OF HCV RNA REPLICATION
PH12014502524B1 (en) Carboxylic acid compounds
MA33939B1 (en) 5-alkynyl-PYRIMIDINE
UA113651C2 (en) MACROCYCLIC PURINS FOR TREATMENT OF Viral INFECTIONS
PE20180318A1 (en) PROCEDURE FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES
CO6480975A2 (en) SMAC MIMETICO
MX2019003738A (en) ANTIVIRAL COMPOUNDS.
CO7131375A2 (en) Bicyclic substituted Uracils and their use
EA201790923A1 (en) DERIVATIVES OF BETULINA
IN2015DN01119A (en)
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
BR112015018504A2 (en) flap modulators
MX2015003021A (en) Glycyrrhetinic acid derivatives with anti-inflammatory activity.
BR112015018491A2 (en) c-19-modified triterpenoids with hiv maturation inhibitory activity
BR112014006559A2 (en) betulinic acid derivatives with antiviral activity
MX340147B (en) PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS OF ABSCYSICAL ACID.
MX2014004920A (en) Novel pyrazine derivatives.
DOP2015000007A (en) METHODS TO PREPARE SUBSTITUTED TRIAZOLOPIRIDINS
CU20130001A7 (en) CRYSTAL FORM DELTA OF THE ARGININE SALT OF PERINDOPRILE, ITS PREPARATION PROCEDURE, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
CR20150160A (en) MACRÓLID DERIVATIVES, ITS PREPARATION AND THERAPEUTIC USE
UY35004A (en) STABILIZED AMORFA FORM OF AGOMELATIN, ITS PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING IT
BR112015030589A8 (en) polymorphic forms of icotinib phosphate, pharmaceutical composition comprising said forms and uses thereof
CO7200259A2 (en) New pyridine derivatives